ClinicalTrials.gg
CompletedNCT01908816ECLIPSEUpdated Aug 12, 2019Results posted

An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.

A Phase 3 interventional study of ranibizumab in Choroidal Neovascularization, Macular Edema and Glaucoma, Neovascular, sponsored by Novartis Pharmaceuticals. Completed at 39 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
10th of 45
270 · median 62
Started
2013
with 5 others
Phase 3
11 of 45
none open now
Registered
35th of 45
by date
Lead sponsor
9 of 45
Novartis Pharmaceuticals

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 10th largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 35th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.

03

Conditions studied

  • Choroidal Neovascularization
  • Macular Edema
  • Glaucoma, Neovascular
  • Diabetic Retinopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active choroidal neovascularization (CNV)
  • Active macular edema (ME)
  • Rubeosis iridis/neovascular glaucoma.
  • Proliferative diabetic retinopathy requiring vitrectomy.

Exclusion criteria

Exclusion Criteria:

  • wet Age-related macular degeneration
  • pathologic myopia
  • pseudoxanthoma elasticum
  • diabetic macular edema
  • retinal vein occlusion
  • \< 18 years of age
  • History of to ranibizumab
  • Use of any systemic anti-angiogenic drugs 3 months before inclusion
  • Women of and Pregnant or nursing (lactating) women.
  • Active or suspected ocular infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
270 participants (actual)

Study arms

  • Experimental
    ranibizumab

    0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.

    Drug: ranibizumab

Interventions

  • One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) for ocular and non-ocular events. Due to early termination, only descriptive analysis was conducted.

    Time frame: 24 months

Secondary outcomes

  1. Change From Baseline Best Corrected Visual Acuity (BCVA) for Patients With Choroidal Neovascularization (CNV) and Macular Edema (ME)

    BCVA change for diseases affecting the macular area either through CNV or ME. BCVA is tested using the ETDRS (Early Treatment Diabetic Retinopathy Study), the Snellen or Monoyer scales. The three scales are designed to measure visual acuity. ETDRS score is expressed in letter, Snellen and Monoyer score in fraction. BCVA assessment is presented in ETDRS after conversion if collected in Snellen or Monoyer. (Monoyer converted to Snellen = 2 x (Monoyer fraction) and Snellen converted to approximate ETDRS letters = 1x log(Snellen fraction). ETDRS letter score was transformed in logMAR unit for statistical analysis (- LogMAR = -(ETDRS-85)/50). The worse ETDRS letter score is 0 (logMAR 2.3) and the best ETDRS letter score is 100 (logMAR -0.3).

    Time frame: 3 months, 12 months

  2. Average Change of Neovascularization Extension for Patients With Neovascular Glaucoma

    The extent of iris neovascularization was assessed by iris photography and graded using the "Teich and Walsh grading system". This grading system measures the number of quadrant at iris pupillary zone or iris ciliary zone where iris neovascularization (NV) is observed. Grade 0 = "No iris vascularization", Grade 1= Less than 2 quadrants of NV at iris pupillary zone, Grade 2 = More than 2 quadrants of NV at iris pupillary zone, Grade 3 =Grade 2 + less than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae; Grade 4 =More than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae)

    Time frame: 3 month, 12 month

  3. Proportion of Patient With Vitreous Cavity Hemorrhage Occurrence for Patient With Proliferative Retinopathy

    Occurrence of postoperative vitreous cavity hemorrhage

    Time frame: 3 months, 12 month

  4. Mean Change From Baseline in Change in Central Retinal Thickness for Patients With CNV (Choroidal Neovascularization) and ME (Macular Edema)"

    CRT in micrometers assessed by Optical Tomography (OCT) at each single study visit. A reduction is thickness indicates an improvement is the lesion area

    Time frame: 3 months, 12 month

  5. Proportion of Patients With Angiographic Leakage

    Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 3. Also any decreases of angiographic leakage was counted between baseline and 3 month.

    Time frame: 3 months, 12 month

  6. Ranibizumab Injection

    Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in 3 months of observation period

    Time frame: 3 months, 12 month

07

Results

Posted Aug 12, 2019
Limitations and caveats
As the study was early terminated, no conclusion could be drawn from this study. The data should be interpreted with cautious as less than half of the patients included in the study (47.0%) completed the visit at Month 12.

Participant flow

open-label, single arm study evaluating the safety of 0.5 mg ranibizumab. Patients received individualized ranibizumab intravitreal injections based on evidence of disease activity. The study was early terminated due to low recruitment that hampered to address the primary endpoint of the study

Participant flow — Overall Study
MilestoneCNV (Choroidal Neovascularization)ME (Macular Edema)RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)PDR/V
Started93845835
Completed0000
Not completed93845835
Withdrew: Subject's no longer requires study drug0001
Withdrew: Protocol deviation1211
Withdrew: Withdrawal by subject0422
Withdrew: Lost to follow-up3542
Withdrew: Death1071
Withdrew: Unsatisfactory therapeutic effect11310
Withdrew: Early termination87604328

Outcome measures

PrimaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability

Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) for ocular and non-ocular events. Due to early termination, only descriptive analysis was conducted.

Time frame:
24 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsCNV (Choroidal Neovascularization)ME (Macular Edema)RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)PDR/V
Non- serious adverse events22110
Serious adverse events11153114
Death1071
SecondaryChange From Baseline Best Corrected Visual Acuity (BCVA) for Patients With Choroidal Neovascularization (CNV) and Macular Edema (ME)

BCVA change for diseases affecting the macular area either through CNV or ME. BCVA is tested using the ETDRS (Early Treatment Diabetic Retinopathy Study), the Snellen or Monoyer scales. The three scales are designed to measure visual acuity. ETDRS score is expressed in letter, Snellen and Monoyer score in fraction. BCVA assessment is presented in ETDRS after conversion if collected in Snellen or Monoyer. (Monoyer converted to Snellen = 2 x (Monoyer fraction) and Snellen converted to approximate ETDRS letters = 1x log(Snellen fraction). ETDRS letter score was transformed in logMAR unit for statistical analysis (- LogMAR = -(ETDRS-85)/50). The worse ETDRS letter score is 0 (logMAR 2.3) and the best ETDRS letter score is 100 (logMAR -0.3).

Time frame:
3 months, 12 months
Reported as:
Mean · Letters
Change From Baseline Best Corrected Visual Acuity (BCVA) for Patients With Choroidal Neovascularization (CNV) and Macular Edema (ME)
LettersCNV (Choroidal Neovascularization)ME (Macular Edema)
3 Month7.3 ± 14.474.5 ± 11.61
12 Month5.7 ± 12.085.2 ± 16.46
SecondaryAverage Change of Neovascularization Extension for Patients With Neovascular Glaucoma

The extent of iris neovascularization was assessed by iris photography and graded using the "Teich and Walsh grading system". This grading system measures the number of quadrant at iris pupillary zone or iris ciliary zone where iris neovascularization (NV) is observed. Grade 0 = "No iris vascularization", Grade 1= Less than 2 quadrants of NV at iris pupillary zone, Grade 2 = More than 2 quadrants of NV at iris pupillary zone, Grade 3 =Grade 2 + less than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae; Grade 4 =More than 3 quadrants of NV at iris ciliary zone and/or ectropion uveae)

Time frame:
3 month, 12 month
Reported as:
Number · Teich and Walsh grading
Average Change of Neovascularization Extension for Patients With Neovascular Glaucoma
Teich and Walsh gradingRanibizumab 0.5 mg
3 Month,Grade 012
3 Month, Grade 16
3 Month, Grade 28
3 Month, Grade 33
3 Month, Grade 42
12 Month, Grade 011
12 Month, Grade 14
12 Month, Grade 22
12 Month, Grade 34
12 Month, Grade 44
SecondaryProportion of Patient With Vitreous Cavity Hemorrhage Occurrence for Patient With Proliferative Retinopathy

Occurrence of postoperative vitreous cavity hemorrhage

Time frame:
3 months, 12 month
Reported as:
Number · Participants
Proportion of Patient With Vitreous Cavity Hemorrhage Occurrence for Patient With Proliferative Retinopathy
ParticipantsPDR/V
3 Month Absent14
3 Month Present3
12 Month Absent12
12 Month Present1
SecondaryMean Change From Baseline in Change in Central Retinal Thickness for Patients With CNV (Choroidal Neovascularization) and ME (Macular Edema)"

CRT in micrometers assessed by Optical Tomography (OCT) at each single study visit. A reduction is thickness indicates an improvement is the lesion area

Time frame:
3 months, 12 month
Reported as:
Mean · μm
Mean Change From Baseline in Change in Central Retinal Thickness for Patients With CNV (Choroidal Neovascularization) and ME (Macular Edema)"
μmCNV (Choroidal Neovascularization)ME (Macular Edema)
3 Month-54.4 ± 104.55-84.4 ± 178.28
12 Month-56.4 ± 69.82-102.0 ± 220
SecondaryProportion of Patients With Angiographic Leakage

Angiography was taken via fluorescein angiography. Any increases of angiographic leakage was counted between baseline and month 3. Also any decreases of angiographic leakage was counted between baseline and 3 month.

Time frame:
3 months, 12 month
Reported as:
Number · Participants
Proportion of Patients With Angiographic Leakage
ParticipantsCNV (Choroidal Neovascularization)ME (Macular Edema)PDR/V
3 Month Absent331
3 Month Present330
12 Month Absent31—
12 Month Present20—
SecondaryRanibizumab Injection

Number of ranibizumab injections needed by decreased visual acuity and/or increasing retinal thickness in 3 months of observation period

Time frame:
3 months, 12 month
Reported as:
Mean · Number of injections
Ranibizumab Injection
Number of injectionsCNV (Choroidal Neovascularization)ME (Macular Edema)RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)PDR/V
3 Month2.5 ± 1.032.7 ± 0.881.7 ± 0.791.6 ± 1.0
12 Month3.8 ± 2.343.9 ± 2.173.0 ± 1.961.7 ± 1.44

Adverse events

Collected over up to 3 years. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Choroidal Neovascularization1/93 (1.1%)11/93 (11.8%)46/93 (49.5%)
Macular Edema0/84 (0%)15/84 (17.9%)66/84 (78.6%)
Rubeosis Iridis/ Neovascular Glaucoma7/58 (12.1%)31/58 (53.4%)40/58 (69%)
Proliferative Diabetic Retinopathy Requiring Vitrectomy1/35 (2.9%)14/35 (40%)21/35 (60%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventChoroidal NeovascularizationMacular EdemaRubeosis Iridis/ Neovascular GlaucomaProliferative Diabetic Retinopathy Requiring Vitrectomy
Ocular hypertension (Study eye)Eye disorders1/931/847/580/35
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/930/841/583/35
Cardiac failureCardiac disorders0/930/844/580/35
Retinal detachment (Study eye)Eye disorders0/930/843/581/35
Glaucoma (Study eye)Eye disorders0/930/842/581/35
Vitreous haemorrhage (Contralateral eye)Eye disorders0/930/842/580/35
Vitreous haemorrhage (Study eye)Eye disorders0/932/842/581/35
FallInjury, poisoning and procedural complications0/930/842/580/35
Intraocular pressure increased (Study eye)Investigations0/931/842/580/35
Renal failureRenal and urinary disorders0/930/842/581/35
Most frequent other events
Showing 10 of 216
Most frequent other events
EventChoroidal NeovascularizationMacular EdemaRubeosis Iridis/ Neovascular GlaucomaProliferative Diabetic Retinopathy Requiring Vitrectomy
Drug ineffective (Study eye)General disorders3/9327/841/580/35
Inappropriate schedule of drug administration (Study eye)Injury, poisoning and procedural complications11/9321/844/581/35
Eye pain (Study eye)Eye disorders6/935/847/583/35
Ocular hypertension (Study eye)Eye disorders0/930/842/583/35
HeadacheNervous system disorders7/934/842/580/35
Incorrect product storage (Study eye)Injury, poisoning and procedural complications4/936/841/580/35
FatigueGeneral disorders2/933/844/580/35
Ulcerative keratitis (Study eye)Eye disorders0/931/842/582/35
Vision blurred (Study eye)Eye disorders2/931/840/582/35
Blood urea increasedInvestigations0/931/840/582/35

Baseline characteristics

A total of 267 patients who received ranibizumab and had at least one post-baseline efficacy assessment were included in the ITT population.

Age, Continuous
Age, Continuous(Years)CNV (Choroidal Neovascularization)ME (Macular Edema)RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)PDR/VTotal
Mean49.7 ± 16.8564.5 ± 13.9970.9 ± 13.0256.5 ± 9.8659.7 ± 16.62
Sex: Female, Male
Sex: Female, Male(Participants)CNV (Choroidal Neovascularization)ME (Macular Edema)RI/NVG (Rubeosis Iridis and Neovacular Glaucoma)PDR/VTotal
Female48352617126
Male45493017141
08

Study locations

39 sites
  • Novartis Investigative Site
    Bobigny cedex, Seine Saint Denis 93009, France
  • Novartis Investigative Site
    Amiens Cedex 1, 80054, France
  • Novartis Investigative Site
    Angers, 49044, France
  • Novartis Investigative Site
    Bordeaux, 33000, France
  • Novartis Investigative Site
    Bordeaux, 33100, France
  • Novartis Investigative Site
    Caen, 14050, France
  • Novartis Investigative Site
    Creteil, 94000, France
  • Novartis Investigative Site
    Ecully, 69130, France
  • Novartis Investigative Site
    Grenoble, 38000, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Lyon Cedex 04, 69317, France
  • Novartis Investigative Site
    Lyon, 69275, France
  • Novartis Investigative Site
    Mantes la jolie, 78201, France
  • Novartis Investigative Site
    Marseille Cedex 8, 13008, France
  • Novartis Investigative Site
    Marseille, F 13008, France
  • Novartis Investigative Site
    Melun, 77000, France
  • Novartis Investigative Site
    Montauban, 82000, France
  • Novartis Investigative Site
    Montpellier, 34000, France
  • Novartis Investigative Site
    Mulhouse cedex, 68070, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Nice, 06000, France
  • Novartis Investigative Site
    Paris cedex 10, 75010, France
  • Novartis Investigative Site
    Paris Cedex 19, 75940, France
  • Novartis Investigative Site
    Paris, Cedex 12, F-75571, France
  • Novartis Investigative Site
    Paris, 75006, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Paris, 75014, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Rouen, 76100, France
  • Novartis Investigative Site
    Saint-Jean, 31240, France
  • Novartis Investigative Site
    Saitnt Herblain, 44819, France
  • Novartis Investigative Site
    St-Priest-en-Jarez, 42270, France
  • Novartis Investigative Site
    Strasbourg Cedex, 67091, France
  • Novartis Investigative Site
    Toulouse, 31077, France
  • Novartis Investigative Site
    Tours, 37000, France
  • Novartis Investigative Site
    Tours, 37044, France
  • Novartis Investigative Site
    Vannes, 56000, France
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Jan 2016, 27 months.

Results were first posted in Aug 2019, 3 years 7 months after primary completion.

Of 15 phase 3 interventional studies under Choroidal Neovascularization, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 35. This study's 27 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2013
First posted
Jul 26, 2013
StartActual
Sep 26, 2013
Primary completionActual
Jan 8, 2016
CompletionActual
Jan 8, 2016
Results first posted
Aug 12, 2019
Last update
Aug 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01908816
Responsible party
Sponsor
First posted
Jul 26, 2013
Start date
Sep 26, 2013
Primary completion
Jan 8, 2016
Completion
Jan 8, 2016
Results posted
Aug 12, 2019
Last update
Aug 12, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion